Xvivo Perfusion AB

Xvivo Perfusion AB

XVIVO · ST · Healthcare / Medical Devices

206.00SEK+3.20 (+1.58%)

Price History

Full chart

Market Stats

Previous Close202.80
Open203.80
Day Range202.80 – 209.80
52-Week Range160.00 – 314.80
Volume96.35K
Market Cap6.85B
P/E (TTM)77.09
Forward P/E34.01
EPS2.82
Dividend Yield0.00%
Beta1.47
50-Day Avg261.26
200-Day Avg242.94

About

Xvivo Perfusion AB (publ), a medical technology company, develops and markets machines and perfusion solutions for assessing usable organs and maintains in optimal condition pending transplantation in Sweden. It operates through Thoracic; Abdominal; Services; and other segments. The company offers Kidney Assist Transport, a portable device that allows hypothermic pulsatile perfusion of donor kidneys with oxygenated solution for up to 24 hours; Liver Assist that provides clinicians a choice of perfusion protocols whether hypothermic, normothermic, sub-normothermic, or a combination; XVIVO System (XPS), a comprehensive ex vivo lung perfusion (EVLP) platform that offers an overview of the entire process; and STEEN Solution, a buffered extracellular solution intended for the assessment of isolated lungs after removal from the donor in preparation for eventual transplantation into a recipient. It also provides Perfadex Plus, an extracellular, low potassium, dextran-based electrolyte preservation solution; XPS Disposable Lung Kit that contains all the necessary devices and tubing to run a normothermic EVLP procedure on the XPS; XVIVO Organ Chamber, a sterile single-use container intended to be used as a temporary receptacle for isolated donor lungs; and XVIVO Lung Cannula Set, a sterile single-use set that connects isolated donor lungs to an extracorporeal perfusion system for ex-vivo assessment. In addition, the company offers Kidney Assist that provides clinicians with a choice of perfusion protocols from hypothermic to normothermic perfusion; and Gisto, an integrated system for organ transportation. It operates in Sweden; The Netherlands; The United States; Italy; North and South America; Asia/Pacific and Oceania; and internationally. Xvivo Perfusion AB (publ) was incorporated in 1998 and is headquartered in Mölndal, Sweden.

Company Details

  • SectorHealthcare
  • IndustryMedical Devices
  • CEOMr. Christoffer Rosenblad
  • Employees197
  • HeadquartersGemenskapens gata 9, Mölndal, Sweden, 431 53, Sweden
  • Websitehttps://www.xvivogroup.com

Leadership

  • Mr. Christoffer RosenbladChief Executive Officer · b. 1975
  • Mr. Kristoffer NordstromCFO and Senior VP of Corporate Strategy & Business Development · b. 1985
  • Ms. Lena Hagman B.Sc.COO & Deputy CEO · b. 1965
  • Ms. Ylva VihojSenior Vice President of Human Resources · b. 1970
  • Dr. Magnus Nilsson Ph.D.Senior Advisor · b. 1956
  • Mr. Johan HolmstromSenior Vice President of Commercial Europe & RoW · b. 1970
  • Mr. Mark ReadeSenior Vice President of North America · b. 1963
  • Mr. Sachin A. SankholkarSenior Vice President of Strategic Marketing · b. 1973

Financials

Income Statement

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue54.43M14.72M68.92M84.70M120.25M138.18M148.34M187.87M220.84M179.86M258.39M415.29M597.54M822.41M812.16M
Growth (%)--72.95%+368.09%+22.90%+41.96%+14.91%+7.36%+26.65%+17.55%-18.56%+43.66%+60.73%+43.88%+37.63%-1.25%
Cost of Revenue10.68M3.31M14.79M20.66M35.28M35.94M34.95M51.91M58.02M46.89M70.11M118.34M152.43M206.00M278.67M
Gross Profit-11.41M54.14M64.05M84.96M102.23M113.40M135.95M162.81M132.97M188.28M296.96M445.11M616.41M533.50M
Gross Margin-77.51%78.55%75.61%70.66%73.99%76.44%72.37%73.73%73.93%72.87%71.51%74.49%74.95%65.69%
Operating Expense-11.20M43.36M57.36M77.75M99.50M106.29M121.95M157.18M167.29M181.30M273.77M440.92M528.06M440.48M
Operating Income28.84M212.00K10.77M6.69M7.21M2.73M7.11M14.00M5.63M-34.31M6.98M23.18M4.19M88.35M93.02M
Operating Margin52.98%1.44%15.63%7.90%6.00%1.98%4.79%7.45%2.55%-19.08%2.70%5.58%0.70%10.74%11.45%
EBITDA-212.00K12.25M11.63M19.14M16.21M22.37M20.25M16.80M-43.33M39.20M39.21M35.05M272.97M153.14M
EBITDA Margin-1.44%17.78%13.73%15.91%11.73%15.08%10.78%7.61%-24.09%15.17%9.44%5.87%33.19%18.86%
Net Income--769.00K8.05M3.74M5.13M1.50M6.26M12.69M4.94M-43.73M8.15M18.43M91.82M172.18M25.16M
Net Income Margin--5.22%11.69%4.41%4.27%1.09%4.22%6.75%2.24%-24.32%3.15%4.44%15.37%20.94%3.10%
R&D4.53M2.31M15.19M23.92M31.09M36.67M39.47M47.93M62.65M56.18M54.04M69.34M135.94M148.33M100.69M
R&D as % of Total Revenue8.33%15.72%22.05%28.24%25.85%26.54%26.61%25.51%28.37%31.23%20.91%16.70%22.75%18.04%12.40%
Interest Expense00123.00K279.00K100.00K101.00K108.00K128.00K349.00K562.00K276.00K1.09M1.19M5.60M44.37M
Interest Expense % of Total Revenue0.00%0.00%0.18%0.33%0.08%0.07%0.07%0.07%0.16%0.31%0.11%0.26%0.20%0.68%5.46%

Balance Sheet

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets140.88M114.52M127.56M201.70M204.18M349.30M538.54M586.61M634.49M1.15B1.54B1.73B2.20B2.40B2.37B
Total Liabilities128.97M25.75M30.93M25.52M19.31M32.88M34.21M46.13M56.97M141.85M257.15M302.95M250.57M245.97M260.65M
Total Equity11.91M88.77M96.64M176.18M184.87M316.41M504.33M540.48M577.52M1.01B1.29B1.43B1.95B2.16B2.11B
Cash2.38M7.78M4.13M48.20M41.03M23.37M195.02M186.26M159.15M353.44M398.70M246.54M545.79M415.52M292.09M
Total Debt-9.09M6.66M-----5.55M7.21M5.72M10.01M31.44M34.04M124.72M
Net Debt-1.31M2.53M-48.20M-41.03M-23.37M-195.02M-186.26M-153.60M-346.22M-392.98M-236.54M-514.35M-381.48M-167.37M

Cash Flow

Currency: SEK2011-12-312012-12-312013-12-312014-12-312015-12-312016-12-312017-12-312018-12-312019-12-312020-12-312021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow14.17M1.67M13.46M-3.74M8.58M12.55M22.19M23.63M29.50M-12.27M-12.06M27.86M46.29M111.29M101.07M
Investing Cash Flow--3.06M-14.85M-15.36M-14.29M-29.73M-35.52M-53.20M-83.84M-266.53M-187.70M-197.62M-161.62M-243.81M-258.41M
Financing Cash Flow-6.99M-2.30M62.70M-1.47M244.00K184.80M19.20M25.55M482.77M234.61M-6.84M418.55M-10.90M72.25M
Capital Expenditure26.00K2.96M12.59M14.97M13.21M20.51M34.93M54.71M83.69M64.68M94.07M130.95M43.02M193.15M101.07M
Free Cash Flow--1.29M874.00K-18.71M-4.63M-7.96M-12.74M-31.08M-54.19M-76.94M-106.13M-103.09M-97.65M-81.86M-151.84M
Dividends Paid-----------7.29M---
FCF to OCF--77.35%6.49%500.11%-53.99%-63.44%-57.43%-131.54%-183.66%627.29%880.11%-370.08%-210.96%-73.56%-150.24%
Dividend Paid to FCF------------7.07%---

Earnings

Report DateFeb 27, 2013Apr 19, 2013Jul 11, 2013Nov 7, 2013Feb 7, 2014May 28, 2014Sep 3, 2014Oct 24, 2014Feb 5, 2015Apr 1, 2015Aug 13, 2015Oct 23, 2015Feb 4, 2016Apr 26, 2016Jul 15, 2016Oct 27, 2016Feb 8, 2017Apr 25, 2017Jul 14, 2017Oct 27, 2017Feb 9, 2018Apr 26, 2018Jul 20, 2018Oct 26, 2018Feb 8, 2019Apr 24, 2019Jul 12, 2019Oct 24, 2019Jan 30, 2020Apr 9, 2020Jul 10, 2020Oct 23, 2020Jan 28, 2021Apr 21, 2021Jul 13, 2021Oct 21, 2021Jan 27, 2022Apr 25, 2022Jul 13, 2022Oct 27, 2022Jan 26, 2023Apr 24, 2023Jul 13, 2023Oct 24, 2023Jan 25, 2024Apr 24, 2024Jul 12, 2024Oct 24, 2024Jan 28, 2025Apr 24, 2025Jul 11, 2025Oct 23, 2025Jan 27, 2026Apr 24, 2026Jul 14, 2026Oct 22, 2026
EPS Estimate-0.060.100.100.10--0.070.100.100.150.190.200.120.09-0.050.000.100.090.130.140.090.160.100.230.310.250.220.14-0.190.070.150.19--0.050.320.29-0.020.210.260.590.600.480.550.660.420.570.800.800.910.632.06-12.651.340.860.84
EPS Actual-0.040.120.090.080.120.090.040.07-0.02-0.020.060.050.130.120.15-0.020.110.050.050.090.230.150.150.000.190.150.080.18-0.070.25-0.46-0.30-0.610.20-0.02-0.040.740.160.170.320.080.510.460.382.710.750.862.861.64-0.300.040.131.011.150.52-
Surprise-100.00%-10.00%-20.00%20.00%--0.00%-120.00%-120.00%-60.00%-73.68%-35.00%0.00%66.67%60.00%--50.00%-44.44%-30.77%64.29%66.67%-6.25%-96.30%-17.39%-51.61%-68.00%-18.18%-150.00%231.58%-757.14%-300.00%-421.05%-60.00%-112.50%155.17%900.00%-19.05%23.08%-86.44%-15.00%-4.17%-30.91%310.61%78.57%50.88%257.50%105.00%-132.97%-93.65%-93.69%107.98%-14.18%-39.53%-
Timing-Pre-marketPre-marketPre-marketPre-market--Pre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketPre-marketAfter-hours

Key Statistics & Ratios

Market Cap6.85B
Enterprise Value7.50B
Trailing P/E77.09
Forward P/E34.01
PEG Ratio0.00
Price / Sales7.65
Price / Book3.49
EPS2.82
Book Value69.85
Revenue (TTM)895.23M
Gross Profit (TTM)647.00M
EBITDA158.26M
Profit Margin9.89%
Operating Margin10.46%
Return on Equity4.13%
Return on Assets2.99%
Shares Outstanding31.50M
Shares Float25.13M
Beta1.47
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%